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ABSTRACT
Newman, Mackenzie. M.S., Department of Pharmacology & Toxicology, Wright State
University, 2013. Effects of Red Diamondback Rattlesnake Venom on Keloid Dermal
Fibroblasts In Vitro
Keloid scarring is an inflammatory healing response to physical injury such as incision or
piercing in the dermis. It is characterized by aberrant extracellular matrix production, the
overaccumulation of mature collagen, and excessive fibroblast proliferation and
migration beyond the borders of the original wound site. This results in swelling,
depigmentation, itchiness, and pain akin to a benign tumor. Although there are myriad
treatments for the condition, most are invasive and exhibit a high recurrence rate.
Previous studies have shown that rattlesnake venom stimulates apoptosis in the skin via
multiple specific mechanisms, largely composed of extracellular matrix and its receptors’
interactions. The goal of this study is to isolate and identify constituents of Crotalus
ruber ruber (C.r.r.) venom that may attenuate keloid fibroblast proliferation. Snake
venom was ultrafiltered and fractionated on a cationic column in a fast protein liquid
chromatography (FPLC) system followed by de-ionization through dialysis membranes.
Normal fibroblasts and keloid samples were treated with fractionated venom and assayed
for cell proliferation and collagen production, while venom was tested for its capacity to
deplete collagen. Separated venom composition was described via MALDI-TOF and
further qualified by specific activity studies. Our results suggest that C.r.r. venom
contains novel peptides and may possess great therapeutic potential toward keloid
scarring.
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BACKGROUND
Skin
The skin is an extremely complex organ that is the body's first defense against
environmental factors. It is the largest organ of the human body with an average surface
area of 1.5-2m2 (Seifert, 2008). The integumentary system includes all layers of the skin,
including the epidermis, dermis, and hypodermis. The epidermis is largely composed of
keratinocytes, the dermis of fibroblasts, and the hypodermis of fibroblasts and
macrophages. Varieties of specialized structures dwell in the skin, including hair follicles,
sweat glands, and nerve terminals. The largest volume of the skin, the dermis, is
composed mainly of extracellular matrix, i.e. collagens (Alberts, 2002), with a low
degree of vascularization.
Wound Healing
Wound healing is one of the oldest studied biological processes (Bhatia, 2004). It is an
immensely complex mechanism that involves myriad cell types and growth factors. It
occurs in three or four principle, overlapping stages, depending on source; these may be
limited to inflammation, proliferation, and maturation (Martin 1997; Broughton, 2006;
Seifert, 2008).
During the first stage of wound healing, the primary goal of the injured tissue is to seal
damaged blood vessels to attain hemostasis (Gousain, 2004). Clotting commences with
the activation of platelets, primarily via the recognition of non-native collagens in the
bloodstream (Nieuwenhuis, 1985) on integrin receptors (Jokinen, 2004). This leads to the
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release of pluripotent cytokines such as transforming growth factor-beta (TGFβ),
plateletactivating factor (PAF) (Parent, 1993), platelet-derived growth factor (PDGF)
(Throckmorton, 1995) and vascular endothelial growth factor (VEGF) (Frank, 1995), and
interleukin-1 (IL1) (Sauder, 1991). TGFβ primarily serves to induce production of
extracellular matrix proteins and proteoglycans such as collagen, fibrin and fibronectin
(Roberts, 1992). Platelet activating factor (PAF), a glycerophosphocholine ester,
modulates leukocyte-driven platelet recruitment and degranulation (Topham, 1998).
PDGF is a potent mitosis inducer that allows cells to skip the G1 restriction checkpoint in
order to drive cellularity of the lesion that also attracts neutrophils and macrophages to
the area (Diegelmann, 2004). IL1 promotes coagulation and helps stimulate the overall
immune response (Sauder, 1991; Yang, 2012). Autocrine signaling in macrophages and
neutrophils perpetuate the inflammatory phase of wound healing.
As leukocytes recede from the active wound, signals from wound-latent VEGF prime the
site for angiogenesis for the second phase of wound healing (Romano, 2002; Bao, 2009;
Wilgus, 2012). The stage, often dubbed "proliferation", lasts for up to two months after
the initial injury. Fibroblast growth factors (FGF) such as FGF-2 and FGF-7 stimulate
keratinocyte growth and migration (Yen, 2013) to stabilize the dermis with the outer
layers of the epidermis; this process of reepithelization is mediated by mesenchymal cells
and macrophages by autocrine TGFβ and paracrine epidermal growth factor (EGF) and
tumor necrosis factor alpha (TNFα) (Chen, 2008). They work along with TGFβ, which is
now secreted primarily by macrophages, neutrophils, and fibroblasts, to encourage
collagen type III production in fibroblasts for the formation of granulation tissue to
protect newly-formed blood vessels and bar infection-bearing microbes from entering the
2

wound site. More fibroblasts are generated by the actions of TGFβ and endothelin-1 on
inactive fibrocytes to further produce matrix, matrix metalloproteases, and cytokines
(Dawes, 1996; Reilkoff, 2011). FGFs and VEGF encourage endothelial cell growth and
drive plasminogen activation (Mossesson, 2005).
The final phase of healing may take years to complete. It is known as "maturation" of the
wound and is characterized as the terminal differentiation of the site. Tissue integrity may
approach its original tensile capacity (Hoying, 2006; Demidova-Rice, 2012). Wounds
contract while maturing due to the action of myofibroblasts in the area; these cells exhibit
characteristics of muscle-derived fibroblasts and secrete large amounts of collagen-I
while depleting stocks of granular collagen-III (Hoying, 2006; Demidova-Rice, 2012).
PDGF and TGFβare major determinants in the progress of the maturation process that
have been shown to directly affect the remodeling capacity of fibroblasts toward the
production of structural matrix proteins such as collagen (Fujiwara, 2005) and laminin
(Malinda, 2008; Stroncek, 2008), glycosaminoglycans including chondroitin and
hyaluronan (Ellis, 1992; Hoffmann, 2012), matrix metalloproteases like MMP1
(collagenase) and MMP2 (gelatinase) (Fujiwara, 2005), and plasmin mediators such as
plasminogen activator inhibitor-1 (PAI1), tissue urokinase (uPA), and kallikrein (Li,
2003; Kishibe, 2012). Tight regulation of the formation and degradation of the
extracellular matrix is crucial during the maturation phase of wound healing for proper
dermostasis
Scarring
Scarring is the final endpoint of wound healing. Scar tissue, which forms throughout the
wound healing process, is constituted largely by fibrillar, cross-linked collagens,
3

especially mature, processed type I (Broughton, 2005).Scarring does not occur in human
fetuses and other organisms with the appropriate regenerative capacity (Leung, 2012).
The formation of scars has been correlated to wound duration (Vowden, 2011); because
numerous ECM members are upregulated during healing, their overproduction is possible
and reinforced by the prevalence of hypertrophic factors in disordered wound healing.
Keloid Phenotype
Keloid scarring is most often encountered as an overhealing response to dermal injury
such as incision, piercing, or burning, though it has been observed to appear after itching,
acne, spontaneously, and by other means (Seifert, 2008; Yi, 2013). Keloids appear more
frequently in women than men by multiple accounts (Furtado, 2009; Gauglitz, 2011). All
keloid scars are hypertrophic scars in nature, but not all hypertrophic scars are keloids
(English, 1999); the ultimate characteristic of the subject is its capacity to recur after
treatment or invade surrounding tissue (Simman, 2003; Fujiwara, 2005; Gauglitz, 2011).
Children and elderly are less likely to form keloids than those aged 10-30 and non-white
racial groups (Juckett, 2009). Some studies (Marneros, 2004; Nakashima, 2010; Zhu,
2013) that focus on families and individual racial groups profile genetic loci which may
be of pharmacological interest reveal, for example, anEGF receptorchain and the
ubiquitin ligase NEDD4. Keloids have been rated as having a considerable effect on
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quality of life by those affected in multiple surveys (Bock, 2006; Furtado, 2009).

Figure 1: Male Earlobe Keloid Harvested for Study
Figure 1 is an example of an earlobe keloid that developed after the removal of ear
gauages.
Keloid Pathology
Keloid scars have been exhibited to possess altered amounts of numerous chemical
species, including but not limited to salts and small radicals (Chau, 2005; Ong, 2010) ,
glycosaminoglycans (Meyer, 2000) and glycoproteins (Babu, 1989; Chung, 2011), fats
(Huang, 2013), oncogenic products (Saed, 1998; Russell, 2010), cytokines (Seifert,
2008), and, by definition, matrix proteins. Keloidal tissue is hypoxic (Kischer, 1992)and
rather acellular compared to acute hypertrophic dermis (Moshref, 2010). It maintains
more heavy metals and gelatins than normal skin (Bang, 2002) at least in part due to the
enhanced production of matrix metalloproteases and ADAMs (Seifert, 2008; Imaizumi,
2009) , which simultaneously perpetuate the condition by encouraging cell migration and
5

fraying the matrix, therefore allowing mutant redifferentation. Sugar derivatives
hyaluronic acid (Meyer, 2000; Seifert, 2008; Hoffmann, 2012) and fibronectin (Babu,
1989; Oliver, 1992) each have been a focus in keloids for their ubiquitous dysregulation
in affected scars for their potential to normalize TGFβsecretion and slow cell migration
due to significant interactions with cytokines, integrins, and ECM.
Keloids overexpress TGFβ. These scars are also commonly described with upregulated
collagen-I (Chipev, 2000; Seifert, 2008), laminin (Lim, 2003), aggrecan (Shih, 2010),
integrins (Szulgit, 2002),thrombins (Smith, 2008), plasmins (Tuan, 2003), and elastins
(Smith, 2008). SMADs and matrix metalloproteases are dysregulated (Seifert, 2008).
Excess collagens clump into amorphous semifibrillar granules that may intercalate other
extra ECM molecules to promote disordered local adhesion. TGFβ-related pathways are
overpromoted due to autocrine signaling in dermal fibroblasts that perpetuates ECM
production (Chipev, 2000; Seifert, 2008; Bran, 2010).

6

Table 1: Differential Characteristics of Overgrown Scars (Seifert, 2008)

Keloid Fibroblasts
Keloid fibroblasts are considered to be the progenitors of keloid scar pathology (Seifert,
2008). Previous research has shown them to show markers of numerous cell types,
including but not limited to osteocytes (Naitoh, 2005), keratinocytes (Felice, 2007),
endothelial cells (Seifert, 2008), chondroblasts (Inui, 2011), chondrocytes (Naitoh, 2005),
and myofibroblasts (Chipev, 2000; Seifert, 2008). These mutants appear primarily at the
margins of scars where the lesion is spreading; fibroblasts isolated from the centers of
keloid scars have been shown to be characteristically normal (Lu, 2007). Compared to
plain hypertrophic fibroblasts, keloidals are larger and fewer in population (Seifert,
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2008). Both their cytoplasmic space and nuclei appear to be engorged compared to
normal fibroblasts. Whereas normal fibroblasts are spindle-shaped with some arm-like
projections, keloids express many acute, long, and non-arrayed appendages (Yi, 2013).
Keloid fibroblasts may develop from senescent cells in the dermis or surrounding tissues;
isolated cells exhibit a larger capacity to migrate and invade versus normal fibroblasts
(Fujiwara, 2005).
TGFβ Signaling
Transforming growth factor-beta (TGFβ) is a cytokine that is involved in numerous
cellular process including cell cycle regulation, differentiation, apoptosis, endosome
formation and degradation, and embryonic development (Kanehisa, 2000; Kanehisa,
2014). It is one of the most promulgated molecules implicated in keloid pathology (Babu,
1992; Seifert, 2008). TGFβis upregulated in nearly all tissues normally but is especially
present in kidney, lung, bone, and placenta (Branton, 1999). It has been shown to
predominate in numerous fibrosis-related disorders, including liver cirrhosis, atrial
fibrillation, pulmonary fibrosis, and keloid scarring (Ueha, 2012). The identification of
TGFβ is attributed to Anita Roberts (Sporn, n.d.). The peptide is classified as an activin
analogue due to its affinity for activin receptors; type I TGFβreceptorsaredescribed as
"activin-like kinase 5" or ALK5 (Nicolas, 2003; The Uniprot Consortium, 2013). Since
its initial isolation, TGFβhas become the titular constituent of a superfamily of proteins
which all contain a similar cystine superstructure. Some of the key members of this group
include nodal, activin, and bone morphogenic proteins which are implicit in neuronal and
embryonic homeostasis (Wu, 2009). The eight reduced cysteines are connected in a
"cysteine knot" pattern while the ninth is covalently bonded to another TGFβ monomer
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(Daopin, 1992).

Figure 2: TGFβ Quaternary Structure (―C‖ is cysteine; capitalization denotes
conserved cystine in TGFβ superfamily) (Hart, 2003; The Uniprot Consortium, 2013)
TGFβ is secreted is a propeptide into the extracellular space as a 390 residue-long chain
that is cleaved to yield the active, 112-residue TGFβ monomer. After cleavage, TGFβ
remains associated to its zymogen core, then known as latency associated peptide (LAP).
The latency complex remains dormant and may be further coordinated by latenttransforming growth factor beta-binding protein 1 (LTBP1) to prevent receptor binding.
When complexed TGFβ is activated, for example by matrix metalloproteases, it binds a
type II receptor dimer which phosphorylates a type I receptor dimer at a serine residue.
Activation of a type I receptor leads to SMAD disengagement from the receptor in the
cytoplasm and gene transcription downstream that allows the production of extracellular
matrix proteins (Roberts, 1998).
Integrin Signaling
Integrins are integral membrane proteins that are a cell's primary sensors of the
extracellular matrix. They play a role in adherence, mechanotransduction, motility, cell
shape, and regulation of the cell cycle (Kanehisa, 2000; Kanehisa, 2014). The surface
receptor is typically encountered a heterodimer of at least one alpha and one beta integrin
subunit while the internal receptor exists as the association of a variety of proteins and
peptides(Brinkerhoff, 2005). A third of all integrins contain an RGD (or similar, such as
9

MVD or KGE) recognition motif that binds sites on collagens and fibronectin to establish
stable matrix fixation (Barczyk, 2009). Large phosphorylated complexes known as "focal
adhesions" constitute stable integrin receptors. Detachment and dissolution of focal
adhesions results in anoikis, a specialized form a cell death related to matrix interaction
(Frisch, 2001). Integrins bind ECM molecules such as collagen, laminin, fibrinogen, and
vitronectin directly (Barczyk, 2001). They also play a vital role in hemostasis; integrin
αIIbβ3, also known as glycoprotein receptor αIIbβ3, is expressed ubiquitously on
platelets and allows them to form a thrombus. This property has become the subject of
medical intervention in recent years (Bledzka, 2013).
Modern Treatments
Scars have been treated with a gamut of medicines throughout history. The most frequent
initial treatment for keloid scars today is corticosteroid injection. Excision is a common
secondary treatment but may be avoided due to the prevalence of recurrence associated
with it. Chemotherapy drugs, radiation therapy, silicone gel sheeting, cryosurgery, and
experimental therapeutics appear often in literature as alternative remedies (Simman,
2003; Juckett, 2009; Hunasgi, 2013). One relevant clinical trial recorded the effects of
bacterial collagenase injected into keloid scars; all patients suffered from gross necrotic
lesions (Kang, 2006). Others focus on the use of unsaturated fatty acids, including those
derived from snake oil, to reduce scarring (Datubo-Brown, 1990); historical, anecdotal
evidence both supports and dissuades the legitimacy of the use of snake oil as a scar
remedy (Louw, 2000; Louw, 2006). Among all the scar treatments described in the
literature, all are far from perfect with respect to disease recurrence (Simman, 2003;
Juckett, 2009; Hunasgi, 2013).
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Snake Venom
Snake venom is a mixture of proteins and peptides that are evolutionarily targeted toward
the capture and digestion of prey. It is produced exclusively in a modified salivary gland
and is secreted through a specialized ductal-fang delivery system to be delivered to its
target. The proteomic components in snake venom exhibit a plethora of biological
activities, such as anticoagulation (Bledzka, 2013), extracellular matrix cleavage
(Teixeira, 2005), hemorrhage (Mori, 1987a), platelet activation (Bledzka, 2013),
thrombus dissolution (Morais-Zani, 2009), angiogenic stimulation (Masaki, 1998),
mitosis via growth factors (Momic, 2011), cell membrane disruption (Mayer, 1993;
Rádis-Baptista, 2011), generation of peroxide (Torii, 1997), ion channel disfigurement
(Dutertre, 2010), and DNA breakdown (Dhananjaya, 2010), and ATP depletion (Kini,
1982). Snake venom also contains numerous short peptides, nucleic acid derivatives, and
organic compounds that are purported to function as inhibitors of the enzymes in venom,
including but not limited to tripeptides (Munekiyo, 2004), nucleotides and nucleosides,
and citrate (Mackessy, 2009).
All snakes have a common ancestor. The evolution of venom composition is tightly
connected to the prey of the snake. Similarly, as snakes age, the size of prey correlates to
that of the predator. Snakes dwell in nearly all habitats across the planet, with the
exception of arctic regions. All snake venoms contain highly targeted neurotoxins,
cytotoxins, myotoxins, and hemotoxins. Most of the toxins the produce the former three
functions act non-enzymatically. Neurotoxic venom components target acetylcholinergic
synapses and ion channels, while cytotoxins and myotoxins bind ion channels,
transporters, and carriers that are typically present in heart, neural, and muscle tissue.
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Hemotoxic venom components are often encountered as enzymes that lyse blood
components and prevent proper thrombus formation in wound healing (Mackessy, 2009).
Snake Venom Therapeutics
Snake venom is an ideal focus for therapeutics because it is targeted toward mammalian
tissue. Research into the uses of venom began, largely, in the 1970s and 1980s, with a
surge in development of rapid proteomic screening tools including FPLC and HPLC. One
of the initial snake venom derivatives to make it to market in the United States was
captopril, an early ACE inhibitor (Smith, 2003). It was developed using QSAR in a
similar fashion to tirofiban, another venom drug and the first to be designed through this
mode. Tirofiban is an anticoagulant that binds platelet integrin αIIbβ3 (Bledzka, 2013).
Eptifibatide, a cyclopeptide based on southeastern pygmy rattlesnake venom, exhibits the
same mechanism of action (Bledzka, 2013). Three high-profile proteases from snake
venom that have been investigated for use in the United States include ancrod (Lowe,
1982), batroxobin (Hao, 2012), and fibrolase (Markland, 2010). Each is described for its
affinity to cleave fibrinogen and its ability to produce a blood clot; these drugs are
implemented as anticoagulants when interference cannot be encountered in platelet
signaling. Study endpoints for the first two were met and the drugs are marketed today;
the third could not pass phase III trials for peripheral arterial occlusion and central venous
accession. Other venom components have been explored in biological systems for
therapeutic potential (Jain, 2010; Kurozumi, 2012; Marangoni, 2013) but none have made
it past phase III trials in the United States.
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Red Diamondback Snake & Venom
Table 2: Snake Venom Peptides (Harvey, 2006; Mackessy, 2009)

Crotalus ruber ruber, colloquially ―red diamondback rattlesnake‖, is the nominate
subspecies of rattlesnake that is indigenous to the southwestern United States and
northern Mexico (Straight, 1992). It is a considerably long snake that is characterized as
producing large volumes of venom (Mackessy, 1985). This red-hued rattlesnake's venom
shares many characteristics of that of Crotalus spp. including sharp proteolytic activity
and ECM-binding properties (Mackessy, 1985; Mori, 1987a; Hamako, 2007). It is
considered to produce weaker biological reactions than that of many other rattlesnakes
(Hamako, 2007; Komori, 2011), but this property is compensated in nature by the snake's
large size which allows more venom to be delivered. Proteolytic activity in venom is
typically higher in adults and snakes in captivity (Mackessy, 2009; Komori, 2011).
Table 3: Previously Identified Proteins and Peptides in Crotalus ruber Venoms
(Mackessy, 1985; Mori, 1987a; Mori, 1987b; Takeya, 1990; Straight, 1992; Takeya,
1993; Hamako, 2007; Komori, 2011; Carey, 2012)
13

The venom of Crotalus ruber subspecies has been assayed for numerous properties and
many proteins and peptides have been sequenced; a summary of these is provided in
Table 3. Notably, a report by Mackessy describes L-amino acid oxidase activity in C.r.r.
venom and evidence from our laboratory and other crotalid sequences suggests that at
least one unsequenced protein similar to apoxin-I exists in C.r.r. venom.
Ruberlysin
A major constituent of C.r.r. venom is ruberlysin, a zinc- and calcium-dependent SVMP
characterized as inducing hemolysis and necrosis in experimental settings. Ruberlysin is a
mildly acidic ~23,321Da protein. It shares homology and identity with many human
matrix metalloprotease, ADAM (A disintegrin and metalloprotease), and ADAMTS
(ADAM with thrombospondin motifs) gene products (Altschul, 1990). Residues 153-155
of ruberlysin are KGD (Komori, 2011; The Uniprot Consortium, 2013) which
functionally act like a traditional RGD motif to bind collagens, integrins, and other ECM
effector molecules.
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Table 4: Specific Cleavages of Various Substrates by Ruberlysin (Schomburg, 2013)

The malleability of the active site of ruberlysin is revealed by various studies on the
specific activity of ruberlysin-containing fractions of snake venom: this SVMP appears to
possess both hydrogen-bonding and nonpolar binding affinity sectors; see Table 4 for
details. Ruberlysin was initially denoted as HT-2 by Stephen P. Mackessy for the median
MW fraction determined by SDS-PAGE. This toxin, along with HT-1 and HT-3, resolved
as one of the venom's three major peak-fractions after HPLC and gel filtration by
absorbance intensity at 280nm (Mackessy, 1985). All fractions possessed hemorrhagic
properties and the first two have been sequenced (Takeya, 1990; Takeya, 1993). There is
some disagreement about the N-terminus of ruberlysin: one source reports glutamine
(The Uniprot Consortium, 2013) in the sequence while another reports a post-translationmodified form, pyroglutamate (Takeya, 1990). A second, modified ruberlysin-like SVMP
has been sequenced and characterized from C.r.r.; rubelase differs from ruberlysin by
four amino acids but was much less potent toward hemorrhage induction (Komori, 2011).
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Hypothesis
The most prominent keloid characteristics are collagen accumulation and production and
increased fibroblast lifespan. Rattlesnake venom is comprised of a number of proteins
and components that normally act synergistically to produce the desired effect in its prey.
Venom components that bind and/or cleave collagens and/or ECM constituents are likely
to directly influence the pathways associated with the proliferation of keloid fibroplasias.
Rattlesnake venom has been shown to stimulate apoptosis in myriad cell types via a
variety of cell-specific mechanisms. These mechanisms include but are not limited to
interactions with the ECM and its receptors, ion carrier disturbance, and membrane
disruption. Due to the unknown nature of the constituents of C.r.r. venom on keloid
fibroblasts, it is necessary to characterize these proteins and peptides and their relevant
properties in order to sieve toward a disease treatment.
The hypothesis is that the separation and identification of these whole venom constituents
by mechanical means will allow a more detailed analysis of the potential of specific
components for therapeutic use. Additionally, the application of these Crotalus ruber
ruber venom components to keloid dermal fibroblasts will elicit more pronounced effects
to phenotypic and proliferative properties compared to those of normal human dermal
fibroblasts.
Specific Aim 1
Develop a working scheme to isolate single proteins and peptides from red diamondback
venom.
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Specific Aim 2
Evaluate the ability of separated C.r.r. venom to cause proliferation or death on keloid
scar and normal dermal fibroblasts.
Specific Aim 3
Determine the efficacy of separated venom components at reducing keloid fibroblast
phenotypic characteristics such as collagen production.
Specific Aim 4
Identify proteins and peptides from fractionated snake venom.
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II. MATERIALS AND METHODS
1. Venom Collection
Crotalus ruber ruber venom was manually procured in the laboratory of animal research
at Wright State University every two weeks. The snake was fed at the end of each twoweek period and its terrarium was tended between venom collections. Two sterile
Eppendorf tubes were covered with fresh parafilm and aligned in front of a red
diamondback snake's fangs. The snake handler, Dr. Sharath Krishna, held the snake from
behind its head and teased it into secreting venom into the containers by waving a
sacrificed mouse in front of its face. The collected product was quickly transported to
Central State University on ice, lyophilized overnight, and stored at -20ºC until further
use.
2. Venom Rectification
Desiccated, frozen venom (around 10mg) was dissolved in one milliliter of distilled,
deionized water (ddH2O) using a Millipore Academic Milli-Q system. For some
experiments, this was rectified into filtrates and insolubles through 10K, 30K, or 50K
molecular weight cutoff filters (Millipore, catalogue UFC501024 (10K), UFC503024
(30K), UFC505024 (50K)) before FPLC treatment. The resultant solutions were
processed using a Bio-Rad DuoFlow FPLC System which employed 100mM
tris(hydroxymethyl)aminomethane (Tris) (A) and 100mM Tris plus 500mM NaCl (B) as
buffers, each adjusted to pH 7.6 using concentrated hydrochloric acid. After sample
injection, 1.8mL of (A) was run at 3mL/minute before a linear gradient was applied
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between the buffers for 13mL at 4mL/minute. At the same rate, isocratic flow was
resumed with 100% (B) for 10.8mL and then 100% (A) for 15mL at the end of the
process. Thirty one-milliliter fractions were collected in total.

Figure 3: Apparatus for Venom Dialysis
Figure 3 displays the methodology used for venom dialysis: the lids, including hinges,
were removed from 1.5mL microfuge tubes with a razor blade (Figure 3C), making sure
to smooth the edge of the tube tops (Figure 3D and Figure 3E). The fractions which
possessed significant absorbance at 214nm were immediately transferred into these
microfuge tubes. Cellulose dialysis membrane (―Spectra/Por6‖ 1kD MWCO, Spectrum
Labs, catalogue 132636) was sectioned, stretched over the top of each tube (Figure 3F),
and secured around the edge with 5/16" elastic bands (Figure 3G). The tubes were then
inverted to test for leaks and placed into individual vials of deionized, distilled water
(Figure 3H). The dialyzing units were allowed to stand for one hour in order fully
equilibrate solute gradients before the water was exchanged; this was repeated four times.

19

The de-salted venom fractions were then deposited into 1.5mL microfuge tubes and
frozen at -20ºC for future experiments.
3. Identification of Venom Components
3.1 Whole Fraction Digestion
The protocols for Sigma product T6567 were adapted for these procedures. Fifteen
microliters of 50mM ammonium bicarbonate solution were mixed with 1.5μL of 100mM
dithiothreitol in a 0.5μL microfuge tube and followed by 25μL of venom fraction. The
mixture was reduced at 95ºC for five minutes in a water bath while 100mM
iodoacetamide was prepared in a foil-wrapped tube. Three microliters of the latter were
added to the cooled samples and incubated in the dark at room temperature for 20
minutes. Trypsin stock was prepared at a concentration of 0.1g/L from proteomics grade
porcine pancreatic trypsin (Sigma, catalogue T6567) and two microliters were added to
each tube. Samples were digested overnight at 30ºC and immediately processed by the
protocols described in 3.3.1.
3.2 Component Digestion
3.2.1 SDS-PAGE Electrophoresis
Twenty microliters of Laemmli sample buffer 2X (Bio-Rad, catalogue 161-0737) with
five percent 2-mercaptoethanol were added to 20μL of sample and this was boiled in a
0.5mL microfuge tube for five minutes. The then-darkened samples were allowed to cool
to room temperature and all forty microliters were pipetted into 4-20% Tris-HCl gels
(Bio-Rad, catalogue 345-0032). Protein stacking was observed for twenty minutes at
100V and separation was performed at 180V for forty-five minutes. After ceasing the
applied voltage, the gel was carefully removed from the electrophoresis chamber and

20

placed in a clean blotting box on an undulating shaker. It was gently swirled with 25mL
of deionized, distilled water for five minutes, fluid was pipetted from the box, and then
the proteins were fixed with 25mL of a 50% acetic acid/7% methanol solution for fifteen
minutes. Fixing solution was discarded and the remnants were washed away with three
five-minute interval water exchanges. The gel was then stained for 45 minutes using
GelCode Blue Safe Protein Stain (Thermo Scientific, catalogue 24594) and excess stain
was washed away by another set of water exchanges. Resolute bands from the finalized
gel were selected and cut out with a razor for further processing. These individual bands
were used immediately in the methodology described in 3.2.2 or stored overnight at 20ºC.
3.2.2 In-Gel Digestion
The methods of Shevchenko et al. (2007) were adapted for these procedures.
Ammonium bicarbonate at a 50mM concentration (C) was used to prepare stock buffers
of 25mM ammonium bicarbonate (D) and 1:1 50mM acetonitrile (ACN)/ammonium
bicarbonate (E). One hundred microliter aliquots of (C) were added to tubes containing
the stained protein bands from 3.2.1 and let stand for 10 minutes. Supernatant was
discarded before 50μL of (E) was added and drawn off twice in ten-minute intervals. The
gel band was dried in a centrifugal evaporator for five minutes while 10mM dithiothreitol
was dissolved into (D). This solution was added in 20μL lots to the tubes and samples
were heated at 37ºC for 60 minutes. Fresh 55mM iodoacetamide was prepped in (D) then
added in 20μL quantities to the cooled samples. Incubation in the dark was permitted for
45 minutes at 37ºC. After the tubes reached room temperature, 100μL of (D) were used to
wash the gel for 10 minutes. The fluid was sucked away before 100μL of (E) was inserted
and taken away for ten minutes two times. Samples were vacuum centrifuged for five
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minutes to ensure full dehydration of the gel disk. Sequencing grade trypsin was brought
to a 20mg/L density in (D). Fifteen microliters were added to each tube along with 15μL
of (D). Samples were digested overnight at 37ºC. Fluid was then removed after
centrifugation, 20μL of 0.3% trifluoroacetic acid (TFA) was pipetted directly onto the gel
band, and three extractions were performed with a 50% ACN/0.3% TFA mixture for ten
minutes each. The volume of the collected supernatant was reduced to 10μL via vacuum
centrifuge. The final samples were stored at -20ºC until processed by the protocols of
3.3.1.
3.3. Mass Spectrometry
3.3.1 Protein Preparation
The resultant peptide mixtures from 3.1 and 3.2.2 were prepared for mass spectrometry
using C18 ZipTips (Millipore, catalogue ZTC18M096). A series of five 1.5mL tubes was
prepared for each sample including one of pure acetonitrile, two of 0.1% TFA, one with
95% ACN/0.3%TFA, and an empty tube for sample collection. ZipTip procedures by
Amanda Freeman were then followed directly. After purification, unknown samples were
mixed 1:1 with 10mg/mL CHCA and 1μL was spotted onto a 384-well ground steel plate.
3.3.2 MALDI-TOF Parameters
A Bruker Daltronics Autoflex III Smartbeam MALDI-TOF mass spectrometer was used
in conjunction with components of the Autoflex software (including Flexcontrol,
Flexanalysis, and Biotools) to obtain all mass spectrometry data. The system was
calibrated with Peptide Standards II (Bruker Daltronics), omitting data points with an
error rate greater than 0.015Da-1, before each use. Default method protocols for MS and
MS/MS measurement were used with no alteration. Laser intensity was set around 80%
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for MS collection, 90% for parent ion identification, and 100% for protein fragmentation.
Data were passed through the MASCOT and Swissprot database servers set exclusively
to search metazoan datasets against a monoisotopic distribution with two or fewer partial
(missed) cleavages, potential oxidation at methionine residues as the sole variable
modification, a mass tolerance of 400ppm, an MS/MS tolerance of 1.0Da, and a charge
state of +1. Peaks of interest were selected from the derived spectra using the Bruker
SNAP processing parameter algorithm with a signal-to-noise threshold of 6 and quality
factor threshold of 50.
4. Peptide Cleavage Assay
Buffers and substrate concentrations suggested in the description for Sigma product
F5135 were used as guidelines for these experiments. FALGPA (N-[3-(2-Furylacryloyl)]L-leucyl-glycyl-L-prolyl-L-alanine) (Crescent Chemical Company, catalogue 51565.01)
was dissolved at 5μg/mL and 1μL was added with 1μL of 0.36mM calcium chloride and
50mM HEPES at pH 7.0 to 10μL of each snake venom fraction. Aliquots of the reactions
were placed in sealed Eppendorf tubes in a 37ºC dark incubator for 45 minutes. Reactions
directly spotted for MALDI-TOF using standard CHCA matrix.
5. In Vitro Studies
5.1 Cell Isolation and Expansion
Wright State University IRB SC#4833was written and filed for these experiments.
Dermal samples were acquired from the earlobe ofa consenting African American male,
age 24, under care in the private office of Dr. Richard Simman. KF1 cell line was
cultured by Dan Yi by the following protocol:

23

"Skin specimens were first washed with phosphate-buffered saline (PBS) (Gibco, Life
TechnologiesTM, USA) three times to exclude erythrocytes, then cut into 2.5mm x 2.5mm
pieces and incubated with 2ml digestion medium containing high glucose Dulbecco's
Modified Eagle's Medium (DMEM) (Gibco, Life TechnologiesTM, USA),5 mg/mL
collagenase/dispase II (RocheDignotics, USA) and 0.25% trypsin (Invitrogen, Life
TechnologiesTM, USA) in 60x15mm tissue culture dish for 8h at the condition of 5%
CO2, at 37oC.Then the tissue suspension was passed through a 100 mm filter
(BiologixResearch Company, USA) to remove any remaining tissue residuals. The
suspension was next centrifuged at 300 G for 8 min to obtain cell pellet. This pellet was
transferred to a T25 cell culture flask cultured with 3 ml total medium containing high
glucose DMEM, 10%FBS (Gibco, Life TechnologiesTM,USA),1% Pen/Strep/Glutamine
(Invitrogen, Life TechnologiesTM, USA) in the condition of 5% CO2, at 37oC. Cells took
approximately 3 days to totally attach to the bottom and reach to confluence in about 10
days. After cells were attached the bottom of the flask, total medium was replaced with
fresh total medium. During cell growth, every 2 or 3 days medium was changed after
PBS washing to exclude the flatting dead cells. Once reaching confluence (named as
Passage 1) cells were detached into a new passage by 0.05% trypsin (Invitrogen,
LifeTechnologiesTM, USA)." [sic] (Yi, 2013)
Normal fibroblasts (NF) were cultured from frozen samples of isolated cells from dermal
tissue of an African American female of similar age to the primary specimen. Keloid
fibroblast cells, derived from a 35-year-old African American female, referred to as KF2,
were purchased from ATCC (product CRL-1762). They were notably late-generation (at
passage 11) and marked as having doubled in population at least ten times since initial
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storage at the company. All fibroblast cell lines were maintained in routine culture using
DMEM modified with glucose (4.5g/L), glutamine, and antibiotics (streptamycin,
amphotericin, and penicillin). Consecutive cultures were passaged with 0.25% trypsin
(Mediatech Cellgro, catalogue 25-050-Cl) using untreated DMEM for washing and full
media for quenching. Incubation followed standard protocol of 5% CO2 and 37ºC
exposure in darkness.

5.2 Fibroblast Proliferation Assays
NF, KF1, KF2, and cells were raised to ~80% confluency in T75 flasks before
trypsinization and plating with nystatin-containing complete DMEM into 8-well chamber
slides. Five slides of each cell type were prepared and allowed to reach full confluency or
slightly overgrow in order to ensure appropriate cell quorum for microscopy. Media was
replaced with 150μL previously-prepared venom dilutions in serum-free DMEM (1e-6
original concentration) and the slides were covered and incubated for six hours at 37ºC
under 5% CO2.
5.3 MTT Assay
Normal fibroblasts were incubated overnight in 96-well plates at a cell density on the
order of 1e5 cells/mL. All reagents were prepared from a stock kit (―TACS(R) MTT Cell
Proliferation Assays‖, Trevigen, catalogue 4890-50-K). Snake venom stock was prepared
at one-half original concentration in DMEM and a 1:10 serial dilution of this was made
down to 1e-7 the initial stock. Media was aliquoted to each well to adjust to a total
volume of 150uL/well after venom addition. Plain media was used as a control. After 3
hours' exposure and incubation, 10uL MTT reagent was added and allowed to react in a
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dark cell culture incubator for three hours. After noting the appearance of purple coloring
in the wells, the plates were removed from the incubator and left overnight in the dark at
room temperature. Plates were read in a plate reader for their absorbance at 535nm.
5.4 Collagen Integrity Assay
The methods of Walsh et al. (1992) were modified for these protocols. Cells were plated
in 96-well microplates with lids and allowed to settle overnight in complete media. Serial
filtered venom fractions were prepared at 1e-6 their original concentrations in DMEM
and applied to cells after removing original media. After four hours’ incubation at 37ºC
under 5% CO2, the plates were immediately placed in a-20ºC freezer and well contents
were allowed to solidify overnight. The following morning, lids were removed and the
plates were wrapped loosely in foil and left overnight in a dry incubator at 37ºC. Wells
were rinsed three times for one-minute increments with 200μL of distilled water.
Picrosirius red dye was prepared by the addition of Direct Red 80 (Sigma, catalogue
365548) to saturated picric acid solution at a 0.1% (w/v) concentration and 100μL was
added to each well for one hour. The wells were rinsed five times with 200μL of 10mM
HCl at 10 seconds per exposure and then 200μL of 0.1M NaOH for 5 minutes. The
stained collagen slurry was gently mixed ten times up and down in a pipettor and
transferred to a new plate for absorbance measurement under a 535nm filter.
5.5.1 van Gieson Staining
The methods of Ellis (2013) and Hunasqi (2013) were modified for these experiments.
Hoescht 33258 was diluted from stock, hemotoxylin was used directly from stock, and
Curtis' stain was made from 9:1:1 saturated picric acid: glacial acetic acid: 1% Ponceau
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S. Nuclei were first bound by Hoescht for 90 minutes and then hemotoxylin was applied
for five minutes. After, Curtis' stain was applied for five minutes to stain collagens. All
dyes were aliquoted into 150μL volumes for each sample and reactions were carried out
at 37ºC, under CO2, in the dark. All wells were carefully rinsed between stains with
ddH2O until no color appeared to leach into solution.
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5.5.2 Microscopy
After the final histological solution was flushed, 4% paraformaldehyde was added to each
well for 30 minutes at 4ºC. The chambers were then removed from the slides and each
was rinsed in ddH2O. Fluorogel with Tris buffer (Electron Microscopy Sciences,
catalogue 17985-10) was applied to coverslips which were immediately affixed to the
slides. A Leica DMR B microscope operated with Leica TASv3.7 software was
employed for all microscopy. Due to physical restrictions, differentiation between
Ponceau S and picrosirius dyes was not detectable so photographs were recorded only for
Hoescht and picrosirius.
5.6 Quantitative Proliferation Assay
All cell lines were individually seeded in 96-well plates in duplicate for the following
procedures. Fibroblasts were allowed to grow past full confluency in order to ensure
appropriate population and matrix density and encourage mild senescence as present in
keloidal tissues. Venom fractions at 1e-6 the original concentration in plain media were
applied in 100μL aliquots to fibroblast cells for four hours in duplicate. After removing
the treated media and rinsing the wells twice with ddH2O, propidium iodide (10μg/mL)
was applied for thirty minutes in the dark at room temperature. Plates were read in a
Packard Fusion microplate reader for fluorescence using an excitation filter at 600nm and
an emission at 620nm.
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III. RESULTS
Develop a strategy to mechanically separate proteins and peptides from red
diamondback venom

Figure 4: Workflow for Experiments
The workflow used for all experiments is displayed in Figure 4. After separation
treatments (red; Aim 1), venom was tested for cell responses (purple; Aim 2), collagenrelated effects (green; Aim 3), and for peptide and protein sequencing (blue; Aim 4).
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Figure 5: FPLC Output after Injection of RDB Venom
Figure 5 shows the absorbance of the FPLC effluent at 214nm, an indicator of peptide
bond concentration, and the fractions chosen for further testing. Fractions exhibiting
resolute peaks in noticeable concentration were selected. Fractions F, G, J, and K each
contain at least two defined peaks.
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Figure 6: SDS-PAGE Gel of 10K, 30K, and 50K Filtered Venom
Figure 6 is an SDS-PAGE separation of RDB venom after the application of different
MWCO filters. RDB venom distilled into resolute classes of peptides. The band around
17kDa is most likely a hemorrhagic toxin, based on early protein gel recovery
experiments (data not shown). The dark band present in both the 50K and 30K filter tops
was unidentifiable via mass spectrometry but suspected to but some form of HT3 given
its size class.
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Figure 7: FPLC Output for Venom Separated via Serial Filtration
Figure 7 shows the FPLC outputs for each post-filtration venom separation. The injection
peaks (the first major peak) in the 10K and 30K diagrams have been scaled out of the
picture in order to accent the differences in the minor peaks. Separation is not visible
given the height of the injection peak. Differential absorbance at 214nm (AU; displayed
on y-axis) was observed in all processes.
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Figure 8: Composite of FPLC Output of Venom Separated via Serial Filtration
Figure 8 shows the relative quantitative protein distribution about the samples passed
through the FPLC. A similar pattern of amplitudes is present in all runs but the
distribution of prominent intensities varies per filtration, implying that different products
are concentrated at different points throughout the filtration process. The height of the
injection peak (the first major peak, truncated in the figure due to size constraints)
changes considerably between the samples due to reduced venom density after successive
filtration; this may have a considerable effect on the resolution of the measured spectra.
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Evaluate the ability of separated C.r.r. venom to cause proliferation or inhibition on
keloid scar and normal dermal fibroblasts

Figure 9: Spectrophotometric Absorbance of MTT Dye at 535nm after Serial
Dilution Venom Exposure at Three Hours
MTT assay is a measure of cell viability: the dye is a bulky, sterically-hindered, opticallyactive and reactive molecule that shifts from visible yellow to purple upon reduction. The
34

results from serial venom dilution exposures, displayed in Figure 9, suggest a mixed
response from fibroblast cells. The untreated group showed a similar response in all
lanes. Color change implying inhibition of cells or the induction of oxidoreductive
signaling—an overall trend downward—was observed in fractions A, C, D, F, and G. The
last two fractions showed sharp responses at the lowest doses used. Proliferation was
suggested by the absorbances recorded from exposure to fraction H. Fractions B, E, and I
exhibited scattered effects. A difference in one aberrant point from each of these datasets
would cause an overall sloping trend to appear more consistent.
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Figure 10: Normal Fibroblasts Exposed to Venom at Various Concentrations over a
1-Day Period
Enzyme contamination is evidenced by the effect of the venom fractions depicted in
Figure 10: numerous fibroblasts were observed to be floating after treatment, their
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spindle-like arms were degraded along with broad surface features of intact ECM, and
acellular debris was accounted at numerous time points in each fraction. Fraction 2
possessed little visible activity, while fractions 3 through 7 caused noticeable fibroblast
detachment and degradation within one hour. Fractions 8 and 9 displayed lytic activity
but some recovery was noted at the end of the 24-hour exposure period; after one day of
treatment, the cells appeared to clump and regenerate their arms. Similar effects were
noted in the other active fractions but to a reduced degree.
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Figure 11: Cells Exposed to 10K, 30K, or 50K MWCO Filtered Venom at Varied
Concentration
Figure 11 shows the effect of filtered venom in serial dilution on normal fibroblasts
afterfour hours. This was performed in order to determine an appropriate dose at which
the cells showed minimal effect. The macroscopic effects are not identical between
dosages, but the overall trend was similar: from high to low exposure, cells detached,
rounded, and tended to float in large, clumped groups, then floated separately, eventually
remaining adherent to the surface of the plate but retaining their rounding. The lowest
doses did not affect the extended fibrous arms of the cells and eventually allowed for
cells to remain grouped on the plate. The lowest exposure, 1e-6 the original venom
concentration, was selected as the safest dosage range observed; a minimal or no effect
was recorded at this level.
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After four hours of venom exposure, fibroblasts, stained for their nuclei and collagen
output, were photographed at 20x; Figures 12 through 15 contain these overlaid images:
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Figure 12: Pictures of Cells Exposed to Venom Fractions from 10K MWCO Filter
and Stained for Collagen and Nuclear Information
Compared to controls, some cell lines showed stronger responses over others. For 10K
filtered venom, Figure 12, normal fibroblasts clumped with fractions 3 and 8 and cell
density rose after exposure to fractions 5, 8, and 16. KF1 cells' nuclei shrank after
exposure to fraction 3. Density rose after the addition of fraction 4 and slightly with
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fraction 14. Fraction 11 caused density to fall. KF2 density was lower after exposure to
fraction 13.

Figure 13: Pictures of Cells Exposed to Venom Fractions from 30K MWCO Filter
and Stained for Collagen and Nuclear Information
Fractions from the 30K filter exhibited effects primarily on normal and young keloid
cells (Figure 13). Fractions 3, 14, 15, and 16 increased density of normal fibroblasts,
while fraction 17 induced clumping. Fractions 8 and 15 lowered seed density and fraction
18 removed all visible cells from the culture. Fraction 13 increased cell density. No
significant effects were observed on the late-generation keloid line.
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Figure 14: Pictures of Cells Exposed to Venom Fractions from 50Kb MWCO Filter
and Stained for Collagen and Nuclear Information
Few effects were noted from the fractions that resulted from the bottoms of the 50K filter
(Figure 14). KF1 cells were absent from culture after exposure to fraction 3 and fractions
4 and 9 resulted in lower cell density.
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Figure 15: Pictures of Cells Exposed to Venom Fractions from 50Kt MWCO Filter
and Stained for Collagen and Nuclear Information
The 50K filter fractions had effects on all cell types (Figure 15). Clumping was observed
in fractions 3, 14, and 21 in the normal fibroblast line. KF1 cell density was lowered by
fractions 8, 16, and 21, while only acellular debris could be detected after exposure to
fractions 13 and 14. Fraction 3 resulted in clumping and fraction 14 caused shrinking of
KF2 cells.
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Figure 16: Cell Staining with Propidium Iodide after Four Hours Exposure to
Snake Venom
Cells exposed to dilute snake venom fractions for four hours showed a multitude of
responses in terms of propidium iodide absorbance as a marker of proliferation; these
reactions in terms of percent change are plotted in Figure 16. Dye absorbance was
normalized to a control for each cell line. No fractions were observed to negatively affect
both keloid lines while simultaneously preserving the normal fibroblast line.
Considerable proliferative effects were observed in the young keloid line (KF1) for many
fractions. Eleven venom components appeared to inhibit the early-stage keloids while
allowing other lines to thrive. These fractions—4 from 10K, 4, 9, and 16 from 30K, 4, 11,
and 13 from the 50K bottom, and 3, 11, and 14 from the 50K top—were selected for
collagenase activity profiling.
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Determine the efficacy of separated venom components at reducing keloid fibroblast
phenotypic characteristics such as collagen production

Figure 17: MS of FALGPA Digests of 10K Filter Venom
FALGPA, a known collagenase substrate, was chosen for these experiments due to its
commonplace use in determining collagenase activity in unknown enzyme mixtures. The
theoretical molar mass of pure FALGPA is 476.53Da. When FALGPA with buffer was
assayed on the mass spectrometer directly, this peak was entirely absent. A mass at
~500Da resolved at high intensity compared to all others in the sample; this was
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considered to be the substrate and may represent the monosodium salt. A representative
spectrum is in Figure 17. Figure 17 displays the digest spectra from the 10K MWCO
filtered venom and Figures 36, 37, and 38 (Appendix 1) contains the FALGPA digest
spectra from the 30K, 50Kb, and 50Kt filtered venoms. The standard’s mass intensity at
500Da was not found to change after samples were subjected to incubation under assay
conditions. A drastic change in the mass intensity at this peak was used as a reference for
collagenase activity. Although mass spectrometry is a semi-quantitative technique at best,
a sharp change in peak height—on the order of ten-thousands of AU—provides a reliable,
strict boolean as to whether the peptide was cleaved. The substrate was regarded as
degraded by all fractions. Attempts were made to couple the loss of the peak at ~500Da
to a gain in some smaller peptide. A mass appeared around 104Da in all fractions which
was not present in the control. The only amino acids with masses around this value, with
regard to the potential addition of sodium ion, are cysteine and threonine, which are not
present in FALGPA. Literature states that bacterial collagenase breaks the substrate
solely between the leucine and glycine residues, resulting in hydrolysis product masses of
~244Da and ~250Da. These masses or the addition of these to small group I cations were
not observed by the SNAP algorithm. However, given the nonspecific nature of known
snake venom enzymes, it is possible that substrate hydrolysis did not cease in the same
fashion as bacterial collagenase.
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Figure 18: Quantitative Collagen Integrity after 4 Hours Venom Exposure
Fractions which exhibited a negative change over KF1 but a positive effect over the other
cell lines were selected from propidium exposure tests to be assayed for their effect on
collagen integrity; Figure 18 is plot of the results. The untreated controls possessed
similar collagen levels between the normal and second keloid fibroblast lines. The
amount of bound Sirius red dye bound by the cell lysates was the least in the NF line and
most in KF2 for all fractions except for 13 from 50Kb and 14 from 50Kt. All snake
venom fractions reduced the integrity of collagens in fraction normal fibroblasts. The
amount of bound dye increased notably in fraction 16 from the 30K filter bottom and
fraction 4 from the 50K filter bottom.
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Identify proteins and peptides from fractionated snake venom

Figure 19: Mass Spectrum of Trypsin-Digested Whole Venom
Figure 19 shows the mass spectrum of whole RDB venom after trypsin treatment. Few
major peaks resolved from the digest. No significant peaks resolved above the range
displayed. According to theoretical digests of RDB proteins based on literature sources,
whole venom contains more resolute peaks than those recorded from our whole venom.
Mascot database identified the venom as containing the protein putative secreted protein
(Q6MYF5_ASPFU; Aspergillus fumigates, Sartorya fumigate) with a significance score
of 60 based on the peptides, while the Uniprot databank searched under the same
conditionsidentified the venom as containing the protein polyferridoxin protein vhuB
(VHUB_METVO; Methanococcusvoltae) with a significance score of 54. A score of 78
is considered a statistically significant hit in MSDB while a score of 67 is significant in
Uniprot.
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Figure 20: Mass Spectra of Venom Fractions
Figure 20 displays the mass spectra of the fractions after trypsin digestion. Fractions A, I,
J, and K were similar as were B and C, and G and H in terms of resolved masses; see
Appendix 3 for specific values. Fractions D and F appeared to contain relatively
abundant, singular digested peptides, at 828.452 and 533.179Da, respectively. The latter
did not appear at appreciable intensity in any other fraction.
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Figure 21: Mass Spectra of Ultrafiltered Venom
Figure 21 shows distinct profiles of post-trypsin-cleaved proteins resulting from the
ultrafiltration of RDB venom. The same derived masses that passed through the filters,
such as 1165 and 2154, and the retained mass of 1405, were consistent among all three
runs, while each fraction possessed unique peaks that were not observed in the other runs,
such as 2251 in the top (retentate) of the 10K filter, 2405 in the bottom (permeate) of the
30K filter, and 1249 in the top (retentate) of the 50K filter.
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Figure 22: Mass Spectra of FPLC-Processed Fractions from 10K Filter from 6001100Da and 1100-4500Da
Figure 22 shows the mass spectra of venom after ultrafiltration through a 10K filter,
FPLC processing, trypsinization, and ziptipping. All fractions contain fragments of 644
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or 650 and 855 or 861Da with the exception of fragments 7, which contains neither, and 2
and 5, which do not contain the high-MW peptides. A mass around 523Da was observed
in fractions 1, 7, and 10. Fractions 5, 7, 9, 10, and 11 gave little contrast in the mass
spectrometer above 1100Da. A mass around 1189Da was measured in fractions 2, 3, 4, 6,
and 8. Fractions 1 and 2, the injection peaks, contained mass intensities around 1276 and
1485.
Figures 25 and 26 (Appendix 1) show the mass spectra of venom after ultrafiltration
through a 30K filter, FPLC processing, trypsinization, and ziptipping. Barring the fifth
fraction, all separations possessed intense masses around 644 or 650, 702, and 855 or
861. Fraction 4 has a 1046Da peak in noticeable quantity, and fractions 2, 5, and 7 have a
623 peak varied within the range of a small number of electron masses. Many of the
spectra are flat above 1100Da, though an 1189 peak was observed in fraction 1. Unique
masses were recorded in fractions 2, 4, 5, 8, 10, and 11, but most lacked stark contrast
overall.
Figure 27 and 28 (Appendix 1) show the mass spectra of venom after ultrafiltration
through a 50K filter, FPLC processing, trypsinization, and ziptipping. All fractions
selected in this range possess peaks around 644 and 855 or 861 and, except for the sixth,
one at 702. Fraction six shares a peak around 689 with fraction five and has a unique
peak at 893.
Figure 29 and 30 (Appendix 1) show the mass spectra of venom that was retained in the
top of a 50K filter after ultrafiltration, FPLC processing, trypsinization, and ziptipping.
The spectrum for the first fraction was nearly empty of real data under 1100Da, but the
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rest contained masses at 644 or 650, 689 or 702, and 855 or 861. Fraction 3 had a peak
around 1189, fractions 1, 4, 5, and 7 had a peptide around 1246, and fractions 1, 2, 4, and
5 each had one around 1679. The rest of the samples provided weakly-contrasted spectra.

Figure 23: Comparison of Fraction 3 (Injection Peak) from Venom Filtrations
Notably different masses resolved between the various fraction volumes from the FPLC,
considering that the conditions at which the machine was ran were the same per trial. The
peptides resolved separately in the 3rd, 11th, 14th, and 21st fractions (Figure 23 and Figures
31, 32, 33, 34, and 35; Appendix 1) were quite distinct; those in the others were similarly
distributed. The 30K and 50Kb cutoffs filtered like mass profiles in the injection effluent,
e.g. fraction 3. Nearly all fractions, no matter the filter, contained a peak around 644 or
650Da.
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Figure 24: Representative Mass Spectra of LIFTs Performed on Venom Fractions
Figures 24 and Figure 39(a-c) (Appendix 1) displays the LIFTs performed on prominent
peaks found in refined, digested C.r.r. venom. The distances between the initial peaks in
the 855, 861, and 877Da LIFTs were similar, as were those between 1060 and 1066, and
4198 and 4312. Intermediate masses generated during LIFT that were present in multiple
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fractions within a 1Da tolerance included 175 in 1933, 1943, 1964, 2186, and 2316, 704
in 889 and 893, 750 in 4198 and 4312, 871 in 1060 and 1249, 889 in 1585, 2709, and
3315, 1758 in 1933 and 1943, and 3485 in 4198 and 4312. Intermediate peaks which
were identified by the default Bruker LIFT method that matched parent masses within a
1Da tolerance included 855 in 1047, 861 in 889, 877 in 1066, 889 in 1585, 893 in 1268,
1060 in 1249, 1287 in 2709, and 2187 in 2316. LIFTs performed below 855Da produced
irresolute spectra with neither peaks nor any chosen by the SNAP algorithm and are not
displayed here.
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Table 5: Proteins Identified in Fractions Indicated via MALDI-TOF with Statistical
Significance

Few coupled MALDI-TOF and LIFT datasets provided statistically-significant evidence
that the venom fractions contained previously-characterized and sequenced proteins in
MSDB and the Swissprot database. Table 5 contains the significant data and Table 6
(Appendix 2) contains data from earlier database searching that used a broad mass
tolerance of 800ppm. The only fractions to contain these proteins were in the top of the
50K filter and all of them were identified as ruberlysin. Because ruberlysin’s mass is
~24kDa, it is possible that there is either at least one similar metalloprotease in the venom
with a high molecular weight such as the one previously named ―HT-3‖ or that
ruberlysin’s size restricts it from passing through the 30K and 50K filters efficiently.
Both the injection fraction (fraction 3) and others that passed through the FPLC indicated
ruberlysin as well, implying that the protein quantity is high enough to contaminate more
samples than the restrictions set by the physical limitations of the buffer system can
overcome. Many other fractions from all filtrations possessed masses that matched or
were similar to those described in theoretical digests of the RDB proteins found in
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databases. Some of these masses include 1192Da, 1246Da, and 1679Da. Theoretical
digests are provided in Appendix 4.
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IV. DISCUSSION
Develop a working scheme to isolate single proteins and peptides from red
diamondback venom
The combination of ultrafiltration and FPLC results in a cost- and time-effective
partitioning system for snake venom proteins and peptides. Sample mixtures can be
reliably resolved into components within hours, depending on the rate of buffer dialysis
after FPLC treatment.
After one passage through our FPLC, mild separation of proteins and peptides was
attained. The mass spectra of the ten fractions showed two basic fragment profiles and all
of them returned similar results after database searching [Newman, 2012]. Simple
ultrafiltration of snake venom showed consistent separation of proteins and peptides: the
same fragments were observed after trypsinization after passage through filters, e.g. a
fragment around 1405Da resolved in the bottom of the 30K and 50K filter but not the
10K filter, when sizing membranes were the only mode of separation employed.
When the techniques were used in tandem, this patterning does not appear to be so clearcut. This may be due to the presence of multiple snake venom metalloproteases of
different size classes in red diamondback venom: the active site is heavily conserved and
the trypsinized fragment is likely to be similar or the same among most venom
metalloproteases, but the complete secreted protein may already be partially cleaved by
the venom itself during in vivo processing and secretion or laboratory handling of the
product. Lyophilization, the first step in handling venom once it has left the animal,
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concentrates the sample into a solid that brings all components into direct contact with
one another. Similarly, the usage of buffers during separation provides charged and steric
cofactors that may modulate the proteolytic activity implicit in red diamondback venom.
The presence of serine proteases and the nonspecific action of SVMPs coupled to their
dimer- and trimer-forming sites may allow early destruction of whole proteins. PII, PIII,
and PIV SVMPs are described as long-chain metalloproteases with individually-active
moieties such as lectins, phospholipase A2s, and disintegrins. A few specific sites on
long-chain metalloprotease may be preferentially autolyzed during venom production and
this process may result in the sequestration of these moieties as individual proteins. For
example, myotoxin (Swissprot accession P24330) shows a high homology when queried
against snake metalloproteases (The Uniprot Consortium, 2013). However, the individual
moieties present in the metalloproteases in C.r.r. venom may not necessarily fall prey to
this type of cleavage; instead, structural damage may result to the quaternary structure of
the intact protein.
Evaluate the ability of separated C.r.r. venom to cause proliferation or death on
keloid scar and normal dermal fibroblasts.
Many effects were observed after the application of C.r.r. venom to dermal fibroblasts.
MTT assay provided evidence of cell inhibition in all fractions and time-response
photography showed signs of inhibition or loss of cells in all fractions. Some of the
effects were immediate and others were gradual; this may be purely to the quantity of
venom in each fraction. One technique used in literature to determine concentration is
based on the absorbance output from FPLC separations, but this measurement requires at
least one venom fraction to have a known protein concentration, and Bradford’s assay did
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not reliably detect protein in a single fraction. The same effects of the time-response—
initial exposure leading to cell rounding and floating, living cells adhered back to the
plate, regenerated their spindles, and spread out across the wells—were observed from a
high to low venom dose. Quantitative propidium iodide staining gave mixed results in
that no fractions appeared to minimally or positively impact normal fibroblasts while
perturbing both keloid lines. The most prominent effects were observed over the young
keloid fibroblast line. These effects were reinforced by the results gathered by
photography of all three cell lines after staining for nuclear information and collagen: few
living cells or only debris was left after exposure to the most fractions. Normal
fibroblasts, which exhibited a high endogenous density and replication rate, showed the
most positive changes toward proliferation.

Determine the efficacy of separated venom components at reducing keloid fibroblast
phenotypic characteristics such as collagen production.
Our intention in testing the capacity of our venom to break down collagen was so that we
could verify the absence or presence of metalloproteases in the venom. Although serine
proteases may cleave collagen, this activity has not been described inC.r.r. venom up to
this point and was not considered during study. FALGPA was chosen for initial studies
due to its prevalence in the characterization of collagenolytic activity of bacterial
collagenases used in research. Few fractions completely degraded the 500Da peak that
our studies attributed to FALGPA entirely but all reduced its intensity to near-zero.
Because mass spectrometry does not perform accurate quantitative measurement and
SVMPs are not exclusively active on peptide substrates, the data derived from this assay
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is not a clear-cut indicator of the absence or presence of metalloproteases. However,
given our results from literature review, venom component identification, and results
from collagen activity assay from whole cells, it is reasonable that all fractions may
contain at least some trace but significant amount of metalloprotease.

Identify proteins and peptides from fractionated snake venom.
LIFT analysis of whole venom and its constituents provided a variety of data after query
against the Swissprot and MASCOT databases. Numerous vertebrate toxins, including
skin-derived non-human antimicrobial peptides, primate defensins, and snake
metalloproteases were returned but none of the former and few of the latter came back
with statistical significance. A preliminary set of data is provided in Table 6 (Appendix
2) and a finalized chart of statistically significant data is provided in Table 5 (Appendix
1). The only metalloprotease to be clearly defined after LIFT was ruberlysin.
Some of the peaks observed after FPLC separation that were analyzed by LIFT were not
clearly defined in the fractions. The parent spectra of these sequences, such as that
derived for a peak between 1165 and 1169 in fractions 4, 5, 8, 16 in from the 10K filter, 9
and 13 from the 50K bottom, and 11 from the 50K top were nondescript about the ranges
when tested at one-dalton intervals. A peak at 1165 was selected as parent because it
produced the cleanest spectrum and may have altered the search algorithm parameters
significantly.
The abundance of these fragments among multiple fractions may imply the presence of
sequentially different constituent peptides. A standard isotopic distribution is typically
observed in a 3-Dalton range for biological material unless it is sulfur-abundant. Due to
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red diamondback venom having been described as containing an alternatively-spliced or
mutant metalloprotease, which differs from ruberlysin by four amino acids and the
numerous other small chain-variant snake venom proteins that have been established in
literature, it is possible that the fractions containing unidentifiable parent fragments carry
alternative forms of similar sequences. Similarly, the fragmentation spectra of numerous
parent ions show a variety of degenerate masses that may show missed cleaves by trypsin
or single amino acid substitutions; these are detailed in the "results" section. It is
entropically favorable for isosteric or physiochemical homologous masses to aggregate
during separation processes so some of these peptides may persist among multiple
fractions.
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V. CONCLUSION
The red diamondback venom used in our studies contains proteins and peptides that have
not been sequenced previously and are not present in the databases used in our search.
Peptide fragments at or close to those which are generated after trypsin digest, such as
that at 1585Da, that are present in multiple fractions of our venom have not been
described in any red diamondback literature to our knowledge. However, our search
proved fruitless in sequencing the entirety of one of these novel proteins. Ruberlysin, the
only protein to be identified significantly, appeared in the top of the 50K filter, but its
mass should have forced it to pass through during 30K and 50K ultrafiltration processes.
The separation techniques employed in this study were limited in grasp but showed a
cost- and time-effective means of efficiently separating the contents of complex protein
mixtures. Future work on this end of the project may include refining the FPLC buffers
and their mixing rates within the system, adding a metalloprotease inhibitor to the venom
that does not affect trypsin, such as 1,10-phenanthroline, and further testing the activity
of the fractions to verify the presence or absence of metalloprotease. A longer FPLC
separation using a taller column may account for these errors outright.
The development of a fast spectrophotometric assay for metalloprotease presence would
be useful for future the rapid screening of separated venom. Attempts made using
FALGPA for this failed to give results.
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The cells used in this study gave valuable results with regard to how different types of
dermal fibroblasts react to enzymatic subjugation. The age of the cells, i.e. how long they
had been isolated in culture may be a relevant focus for future keloid research with regard
to snake venom. Many snake venom fractions, especially those which showed minimal
effect on normal fibroblast cells and pronounced effects on the keloids, may be of
pertinent interest for therapeutic use; in this vein, longer time-response trials are required
to eke out the real potential of the venom. All of the photographs of cells give a direction
for the time and dose required of the venom proteins and peptides, but much more
quantitative data is necessary for a valid assessment of the venom to be made.
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VI. APPENDIX
APPENDIX 1: RESULTS

Figure 25: Mass Spectra of FPLC-Processed Fractions from 30K Filter from 6001100Da
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Figure 26: Mass Spectra of FPLC-Processed Fractions from 30K Filter from 11004500Da
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Figure 27: Mass Spectra of FPLC-Processed Fractions from 50Kb Filter from 6001100Da

Figure 28: Mass Spectra of FPLC-Processed Fractions from 50Kb Filter from 11004500Da
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Figure 29: Mass Spectra of FPLC-Processed Fractions from 50Kt Filter from 6001100Da

Figure 30: Mass Spectra of FPLC-Processed Fractions from 50Kt Filter from 11004500Da
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Figure 31: Comparison of Fraction 4 MS from Venom Filtrations

Figure 32: Comparison of Fraction 8 MS from Venom Filtrations

Figure 33: Comparison of Fraction 11 MS from Venom Filtrations
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Figure 34: Comparison of Fraction 14 MS from Venom Filtrations

Figure 35: Comparison of Fraction 21 MS from Venom Filtrations

70

Figure 36: MS of FALGPA Digests of 30K Filter Venom
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Figure 37: MS of FALGPA Digests of 50Kb Filter Venom
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Figure 38: MS of FALGPA Digests of 50Kt Filter Venom
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Figure 39a: Mass Spectra of LIFTs Performed on Venom Fractions
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Figure 39b: Mass Spectra of LIFTs Performed on Venom Fractions
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Figure 39c: Mass Spectra of LIFTs Performed on Venom Fractions
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APPENDIX 2:
Table 6: Database Query Returns with Variable Search Parameters
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APPENDIX 3: MALDI-TOF Mass Data Derived by SNAP Algorithm
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APPENDIX 4: Theoretical Digests of Known RDB Proteins, with Zero Missed
Cleavages
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